Curing Hepatitis C: Options for Treatment
In a breakthrough publication, leading hepatologist and hepatitis C expert Gregory Everson, M.D. provides state-of-the-science information to guide patients through the diagnosis and treatment of hepatitis C. Until recently, hepatitis C was considered incurable. “Curing Hepatitis C” outlines the new treatment protocols that offer the outcome of complete cure from this disease.
“Curing Hepatitis C” provides an indispensable and comprehensive overview for the nearly 160 million people worldwide and 4 million Americans diagnosed with hepatitis C. Perhaps most importantly, “Curing Hepatitis C” provides hope.
Author’s Statement
“Hedy Weinberg and I wrote five editions of Living with Hepatitis C: A Survivor’s Guide for the purpose of providing patients and caregivers a resource that could serve as an authoritative readily-available resource. I provided the medical information and Hedy provided the patient perspective by interviewing many patients with HCV to provide a personal connection for the reader. In this new book, I have focused on issues and questions related to the current new standard of treatment, Triple Therapy, and the exciting emerging therapies. As treatment continues to improve, eradication of HCV infection will become increasingly common – the new paradigm will be living without, not with, hepatitis C. Perhaps I am overly optimistic, but I believe that it is entirely possible that the emerging treatments will be so potent and effective that nearly every patient with chronic hepatitis C may be cured by future antiviral therapies!”
Curing Hepatitis C: Current and Future Options for Treatment
Written by Gregory T. Everson, Foreword by Gene Schiff
Published by Hatherleigh Press
ISBN: 978-1-57826-425-4
Available wherever books are sold
Dr. Everson recently wrote an article that was published in the September 2016 Journal of Hepatology. His editorial focuses on a paper that suggests that once a person on the waiting list is cured, there is a chance that the listed person could improve to the point of delisting and potentially avoiding liver transplant. His editorial discusses the PROs and CONs of the article and provides perspective on the issue. Read the article here.
Dr. Gregory Everson is Chief Executive Officer and Managing Member of HepQuant, LLC, a company he founded in 2007 with a small group of investors.
Dr. Everson received his MD degree from Cornell Medical College, NY, NY and is currently Past Professor of Medicine and Past Director of Hepatology at the University of Colorado, Denver. He is a distinguished Fellow of several professional societies and has published over 300 original papers, books, and book chapters in peer-reviewed journals that include Hepatology, Clinics in Liver Disease, Gastroenterology, Journal of Hepatology, New England Journal of Medicine, The American Journal of Gastroenterology, Alimentary Pharmacology and Therapeutics, and Expert Reviews in Gastroenterology and Hepatology. He has authored several “self-help” books on a variety of liver diseases: Living with Hepatitis C: A Survivor’s Guide, Curing Hepatitis C, Living with Hepatitis B: A Survivor’s Guide, and Living with Hemochromatosis: Answers to your Questions about Iron Overload.
He is a frequently invited speaker and has presented his work at clinical and scientific meetings nationally and internationally. His research has spanned many topics in both basic and clinical hepatology – bile acid and cholesterol metabolism, mechanisms of gallstone formation, effects of female steroid hormones on liver metabolism, hepatitis C, liver transplantation, polycystic disease, and quantifying the function of the liver with unique minimally invasive tests.
He is an advisor and consultant to foundations and industry. Dr. Everson is a member of the American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), American Society of Transplantation (AST), the International Liver Transplant Society (ILTS). He is past member of the Transplant Hepatology Committees of the American Board of Internal Medicine and Accreditation Council for Graduate Medical Education. After over twenty years of research, Dr. Everson founded HepQuant, LLC in order to commercialize his invention of novel technology for noninvasive assessment of chronic liver disease.
Last Updated on April 24, 2020
Share this page
